Selux Diagnostics, a Boston-based biotechnology company whose mission is to combat superbug infections and fight antimicrobial resistance (AMR), announced they have received an additional $48 million to launch their next phase of commercialization of the Selux Next Generation Phenotyping (NGP) System within the US. RA Capital Management led this new funding round with participation from Northpond Ventures, Sands Capital, and Schooner Capital.
Selux’s NGP System is a rapid Antibiotic Susceptibility Testing (AST) platform that delivers results days faster than the current standard of care. And AST, the critical diagnostic test that informs personalized antibiotic therapy, can take up to 3-5 days for a result.
The Selux NGP System can deliver same-day AST results, which will transform patient care and reduce the overreliance on broad spectrum antibiotics, a significant factor in the increase of superbugs.
Along with the $48 million, Selux received their third FDA clearance earlier this year making the Selux NGP System the only FDA-cleared single-platform rapid AST technology that can deliver AST results in a matter of hours for isolated colonies and positive blood culture. And the science and technology behind the Selux NGP System is redefining speed and AST performance, combatting superbugs head-on.
KEY QUOTE:
“Thanks to our partners who believe in the importance of new and innovative technology and the hard-working team at Selux, we are able to lead a new era in personalized diagnostics.”
– Steve Lufkin, CEO of Selux Diagnostics
